News related to Crestor (Rosuvastatin) and/or conditions it is approved for
Crestor® Reduced Risk Of Cardiovascular Events In Women By Nearly Half In New Analysis Of Jupiter Study
Source: Cardiovascular / Cardiology News From Medical News Today [2009.11.19]
A new analysis of 6,801 women in the JUPITER study showed CRESTOR® (rosuvastatin calcium) 20 mg significantly reduced cardiovascular (CV) events (defined as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by nearly half (46 percent; p=0.002 vs.
Crestor shows equal or better benefit to women (Reuters)
Source: Y! Health Cholesterol News [2009.11.17]
Reuters - A fresh look at data from a landmark study showed that AstraZeneca's powerful cholesterol fighter Crestor dramatically cut deaths, heart attacks and strokes in women at least as much as in men, providing new evidence of the drug's benefits in a previously understudied population.
AHA: Drilling Down in JUPITER Confirms Benefit for Women (CME/CE)
Source: MedPageToday.com - medical news plus CME for physicians [2009.11.19]
ORLANDO (MedPage Today) -- A subset analysis of data from the JUPITER trial indicates that apparently healthy women treated with rosuvastatin (Crestor) reduced their relative risk of major cardiovascular events by 46%, slightly higher than the 42% reduction seen in men.
|
